(Q37582072)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Tim Rhodes

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Carla Treloar

series ordinal

1

1 reference

21 August 2017

Tim Rhodes

series ordinal

2

1 reference

21 August 2017

language of work or name

1 reference

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

Qualitative Health Research

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

1321-1334

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

Global estimates of prevalence of HCV infection among injecting drug users.

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Women's perspectives on chronic illness: ethnicity, ideology and restructuring of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Living with a chronic illness: Chinese-Canadian and Euro-Canadian women with diabetes--exploring factors that influence management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Consumer participation in the planning and delivery of drug treatment services: the current arrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Chronic illness as biographical disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Living with the stigma of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Evaluating meta-ethnography: a synthesis of qualitative research on lay experiences of diabetes and diabetes care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Therapeutic challenges in hepatitis C-infected injection drug using patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

What do patients consider when making decisions about treatment for hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Diagnosed with Hepatitis C: a descriptive exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Breaking the silence surrounding hepatitis C by promoting self-efficacy: hepatitis C public service announcements

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

High hepatitis C incidence in new injecting drug users: a policy failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Treatment for hepatitis C virus infection among current injection drug users in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

The depiction of stigmatization in research about hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Critical analysis of everyday self-care decision making in chronic illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

The social production of hepatitis C risk among injecting drug users: a qualitative synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montréal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Integrating HCV services for drug users: a model to improve engagement and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

The lived experience of men and women with hepatitis C: implications for support needs and health information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Public opinion on needle and syringe programmes: avoiding assumptions for policy and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Deficit models and divergent philosophies: Service providers’ perspectives on barriers and incentives to drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Infection control in the context of hepatitis C disclosure: implications for education of healthcare professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

"Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Beyond prevention? Injecting drug user narratives about hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Preventing hepatitis C: ‘Common sense’, ‘the bug’ and other perspectives from the risk narratives of people who inject drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Trust, disruption and responsibility in accounts of injecting equipment sharing and hepatitis C risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Citizens who inject drugs: the ‘Fitpack’ study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049732309341656

21 January 2018

Identifiers

DOI

10.1177/1049732309341656

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19690211%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference